alpha-glucosidase inhibitor

(redirected from a-glucosidase inhibitor)

α-glucosidase inhibitor

an oral agent that aids in the control of diabetes mellitus by delaying the absorption of glucose from the digestive system.

alpha-glucosidase inhibitor

any of a group of oral antihyperglycemic agents that act by competitive inhibition of alpha-glucosidase, delaying intestinal carbohydrate absorption and lessening postprandial increases in glucose levels.

alpha-glucosidase inhibitor

An oral drug that lowers blood sugars by preventing carbohydrate absorption from the gastrointestinal tract.
See also: inhibitor

α-glu·co·si·dase in·hib·i·tor

(glū-kō'si-dās in-hib'i-tŏr)
Oral agent that aids control of diabetes mellitus by delaying absorption of glucose from digestive system.
References in periodicals archive ?
By regulating its action through a-glucosidase inhibitor is an attractive approach for controlling blood glucose levels for the treatment of Type II diabetes in modern era of medicine [41].
17) Thus, long-term prophylaxis with this a-glucosidase inhibitor in high-risk individuals with impaired glucose tolerance could provide a pharmacological option, along with lifestyle modification, to help reduce the burden of type 2 diabetes.
Comment: The options to replace rosiglitazone include an a-glucosidase inhibitor, glinide, amylin analog, GLP-1 receptor agonist, DPP-4 inhibitor, and insulin.
These include the a-glucosidase inhibitors, glinides (rapid-acting insulin secretagogues) and insulins (rapid-acting insulin analogues, biphasic [premixed] insulins, inhaled insulin, human regular insulin).
The thiazolidinedione troglitazone and the a-glucosidase inhibitors have unique effects that make them useful as monotherapy in some patients.
SB1 was therefore selected for on-line HPLC-BCD analysis to identify the major a-glucosidase inhibitors.
a-Glucosidase inhibitors for patients with type 2 diabetes mellitus: results from a Cochrane systematic review and meta-analysis.
Mitiglinide indications: Improvement in and treatment of postprandial glucose transition, optionally in combination with a-glucosidase inhibitors, Metformin or thiazolidinediones, in patients with type 2 diabetes mellitus
A traditional Chinese medical herb, Sangzhi (Ramulus mori), appears to have properties similar to those of a-glucosidase inhibitors.